Interaction of dietary fatty acids with tumour necrosis factor family cytokines during colon inflammation and cancer

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Hofmanová, Jiřina ^a   Straková, Nicol ^a   Vaculová, Alena Hyršlová ^a   Tylichová, Zuzana ^a,b   Šafaříková, Barbora ^a,b   Skender, Belma ^a   Kozubík, Alois ^a,b  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BUTYRIC ACID; FAS LIGAND; FATTY ACID; POLYUNSATURATED FATTY ACID; SHORT CHAIN FATTY ACID; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; BUTYRIC ACID DERIVATIVE; CYTOKINE; DOCOSAHEXAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; UNSATURATED FATTY ACID;

ARTICLE; CANCER PREVENTION; CHRONIC INFLAMMATION; COLITIS; COLON CANCER; COLON CARCINOGENESIS; CYTOKINE PRODUCTION; DIETARY FIBER; ENTERITIS; FAT INTAKE; HUMAN; NEOPLASM; NONHUMAN; PROTEIN PROTEIN INTERACTION; ANIMAL; APOPTOSIS; COLON; DIET; INFLAMMATION; INTESTINE; METABOLISM; MITOCHONDRION; MOUSE; PATHOLOGY;

ANIMALS; APOPTOSIS; BUTYRATES; COLON; CYTOKINES; DIET; DOCOSAHEXAENOIC ACIDS; FATTY ACIDS, UNSATURATED; HUMANS; INFLAMMATION; INTESTINES; MICE; MITOCHONDRIA; NEOPLASMS; NF-KAPPA B; TUMOR NECROSIS FACTORS;

EID: 84901020442     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/848632     Document Type: Article

References (199)

1. Bertrand F. E., Angus C. W., Partis W. J., Sigounas G., Developmental pathways in colon cancer: crosstalk between WNT, BMP, Hedgehog and Notch. Cell Cycle 2012 11 4344 4351
2. Gunther C., Neumann H., Neurath M. F., Becker C., Apoptosis, necrosis and necroptosis: cell death regulation in the intestinal epithelium. Gut 2013 62 1062 1071
3. Ahmed F. E., Colon cancer: prevalence, screening, gene expression and mutation, and risk factors and assessment. Journal of Environmental Science and Health C: Environmental Carcinogenesis and Ecotoxicology Reviews 2003 21 2 65 131 2-s2.0-0345708286 10.1081/GNC-120026233
4. Grady W. M., Carethers J. M., Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008 135 4 1079 1099 2-s2.0-53049087109 10.1053/j.gastro.2008.07.076
5. Lifshitz S., Lamprecht S. A., Benharroch D., Prinsloo I., Polak-Charcon S., Schwartz B., Apoptosis (programmed cell death) in colonic cells: from normal to transformed stage. Cancer Letters 2001 163 2 229 238 2-s2.0-0035952367 10.1016/S0304-3835(00)00624-8
6. Zhivotovsky B., Orrenius S., Carcinogenesis and apoptosis: paradigms and paradoxes. Carcinogenesis 2006 27 10 1939 1945 2-s2.0-33749572210 10.1093/carcin/bgl035
7. Chen L., Park S. M., Tumanov A. V., CD95 promotes tumour growth. Nature 2010 465 492 496
8. Balkwill F., Mantovani A., Inflammation and cancer: back to Virchow? The Lancet 2001 357 9255 539 545 2-s2.0-0035901090 10.1016/S0140-6736(00)04046-0
9. Lakatos P. L., Lakatos L., Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World Journal of Gastroenterology 2008 14 25 3937 3947 2-s2.0-53449086211 10.3748/wjg.14.3937
10. Itzkowitz S. H., Yio X., Inflammation and cancer-IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. American Journal of Physiology-Gastrointestinal and Liver Physiology 2004 287 1 G7 G17 2-s2.0-3042599473 10.1152/ajpgi.00079.2004
11. Gaur U., Aggarwal B. B., Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochemical Pharmacology 2003 66 8 1403 1408 2-s2.0-0642283970 10.1016/S0006-2952(03)00490-8
12. Boyle P., Leon M. E., Epidemiology of colorectal cancer. British Medical Bulletin 2002 64 1 25 2-s2.0-0036031826 10.1093/bmb/64.1.1
13. Yamamoto T., Nakahigashi M., Saniabadi A. R., Review article: diet and inflammatory bowel disease-epidemiology and treatment. Alimentary Pharmacology and Therapeutics 2009 30 2 99 112 2-s2.0-67649875285 10.1111/j.1365-2036.2009. 04035.x
14. McEntee M. F., Whelan J., Dietary polyunsaturated fatty acids and colorectal neoplasia. Biomedicine and Pharmacotherapy 2002 56 8 380 387 2-s2.0-0036773459 10.1016/S0753-3322(02)00254-8
15. Weijenberg M. P., Lüchtenborg M., de Goeij A. F. P. M., Brink M., van Muijen G. N. P., de Bruïne A. P., Goldbohm R. A., van den Brandt P. A., Dietary fat and risk of colon and rectal cancer with aberrant MLH1 expression, APC or KRAS genes. Cancer Causes and Control 2007 18 8 865 879 2-s2.0-34547231601 10.1007/s10552-007-9032-6
16. Schrenk D., Dietary fiber, low-molecular-weight food constituents and colo-rectal inflammation in animal models-a review. Molecular Nutrition and Food Research 2009 53 10 1281 1288 2-s2.0-70350031359 10.1002/mnfr.200800576
17. Putaala H., Mäkivuokko H., Tiihonen K., Rautonen N., Simulated colon fiber metabolome regulates genes involved in cell cycle, apoptosis, and energy metabolism in human colon cancer cells. Molecular and Cellular Biochemistry 2011 357 1-2 235 245 2-s2.0-84857403112
18. Sethi G., Shanmugam M. K., Ramachandran L., Kumar A. P., Tergaonkar V., Multifaceted link between cancer and inflammation. Bioscience Reports 2012 32 1 1 15 2-s2.0-84856919722 10.1042/BSR20100136
19. Vendramini-Costa D. B., Carvalho J. E., Molecular link mechanisms between inflammation and cancer. Current Pharmaceutical Design 2012 18 3831 3852
20. Chiba T., Marusawa H., Ushijima T., Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology 2012 143 550 563
21. Danese S., Mantovani A., Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer. Oncogene 2010 29 23 3313 3323 2-s2.0-77953479589 10.1038/onc.2010.109
22. Tappenden K. A., Inflammation and intestinal function: where does it start and what does it mean? Journal of Parenteral and Enteral Nutrition 2008 32 6 648 650 2-s2.0-54249104930 10.1177/0148607108325177
23. Andoh A., Yagi Y., Shioya M., Nishida A., Tsujikawa T., Fujiyama Y., Mucosal cytokine network in inflammatory bowel disease. World Journal of Gastroenterology 2008 14 33 5154 5161 2-s2.0-58149265605 10.3748/wjg.14.5154
24. Kraus S., Arber N., Inflammation and colorectal cancer. Current Opinion in Pharmacology 2009 9 4 405 410 2-s2.0-68849127181 10.1016/j.coph.2009.06.006
25. Klampfer L., Cytokines, inflammation and colon cancer. Current Cancer Drug Targets 2011 11 4 451 464 2-s2.0-79955585058 10.2174/156800911795538066
26. Monteleone G., Pallone F., Stolfi C., The dual role of inflammation in colon carcinogenesis. International Journal of Molecular Sciences 2012 13 11071 11084
27. Rizzo A., Pallone F., Monteleone G., Fantini M. C., Intestinal inflammation and colorectal cancer: a doubleedged sword? World Journal of Gastroenterology 2011 17 26 3092 3100 2-s2.0-79961047053 10.3748/wjg.v17.i26. 3092
28. Popivanova B. K., Kitamura K., Wu Y., Kondo T., Kagaya T., Kaneko S., Oshima M., Fujii C., Mukaida N., Blocking TNF- in mice reduces colorectal carcinogenesis associated with chronic colitis. The Journal of Clinical Investigation 2008 118 2 560 570 2-s2.0-38849171267 10.1172/JCI32453
29. Waldner M. J., Neurath M. F., Cytokines in colitis-associated cancer: potential drug targets? Inflammation and Allergy-Drug Targets 2008 7 3 187 194 2-s2.0-55249119556 10.2174/187152808785748137
30. Yan S. R., Joseph R. R., Rosen K., Reginato M. J., Jackson A., Allaire N., Brugge J. S., Jobin C., Stadnyk A. W., Activation of NF- B following detachment delays apoptosis in intestinal epithelial cells. Oncogene 2005 24 43 6482 6491 2-s2.0-26944491533 10.1038/sj.onc.1208810
31. Chapkin R. S., Davidson L. A., Ly L., Weeks B. R., Lupton J. R., McMurray D. N., Immunomodulatory effects of (n-3) fatty acids: putative link to inflammation and colon cancer. Journal of Nutrition 2007 137 1 200S 204S 2-s2.0-33845981059
32. Min/+ mouse. Cytokine 2012 57 1 113 119 2-s2.0-84155172104 10.1016/j.cyto.2011.09.027
33. Aggarwal B. B., Gupta S. C., Kim J. H., Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 2012 119 3 651 665 2-s2.0-84856074741 10.1182/blood-2011-04-325225
34. Bhardwaj A., Aggarwal B. B., Receptor-mediated choreography of life and death. Journal of Clinical Immunology 2003 23 5 317 332 2-s2.0-0041330433 10.1023/A:1025319031417
35. Walczak H., Krammer P. H., The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Experimental Cell Research 2000 256 1 58 66 2-s2.0-0034630161 10.1006/excr.2000.4840
36. Nagata S., Apoptosis by death factor. Cell 1997 88 3 355 365 2-s2.0-0030892234 10.1016/S0092-8674(00)81874-7
37. MacFarlane M., TRAIL-induced signalling and apoptosis. Toxicology Letters 2003 139 2-3 89 97 2-s2.0-0037418619 10.1016/S0378-4274(02)00422-8
38. Özören N., El-Deiry W. S., Defining characteristics of types I and II apoptotic cells in response to TRAIL. Neoplasia 2002 4 6 551 557 2-s2.0-0036859738 10.1038/sj.neo.7900270
39. Sprick M. R., Walczak H., The interplay between the Bcl-2 family and death receptor-mediated apoptosis. Biochimica et Biophysica Acta 2004 1644 2-3 125 132 2-s2.0-1442359848 10.1016/j.bbamcr.2003.11.002
40. Wu W., Liu P., Li J., Necroptosis: an emerging form of programmed cell death. Critical Reviews in Oncology/Hematology 2012 82 249 258 2-s2.0-80053371489 10.1016/j.critrevonc.2011.08.004
41. Welz P. S., Wullaert A., Vlantis K., Kondylis V., Fernández-Majada V., Ermolaeva M., Kirsch P., Sterner-Kock A., van Loo G., Pasparakis M., FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation. Nature 2011 477 7364 330 334 2-s2.0-80052850704 10.1038/nature10273
42. Beutler B., Cerami A., Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 1986 320 6063 584 588 2-s2.0-0022485610
43. Jäättelä M., Biology of disease: biologic activities and mechanisms of action of tumor necrosis factor- /cachectin. Laboratory Investigation 1991 64 6 724 742 2-s2.0-0025874544
44. Tracey K. J., Cerami A., Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annual Review of Medicine 1994 45 491 503 2-s2.0-0028244816 10.1146/annurev.med.45.1.491
45. Reinecker H. C., Steffen M., Witthoeft T., Pflueger I., Schreiber S., MacDermott R. P., Raedler A., Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clinical and Experimental Immunology 1993 94 1 174 181 2-s2.0-0027451455
46. Scheidereit C., I B kinase complexes: gateways to NF- B activation and transcription. Oncogene 2006 25 51 6685 6705 2-s2.0-33750443289 10.1038/sj.onc.1209934
47. Numata A., Minagawa T., Asano M., Nakane A., Katoh H., Tanabe T., Functional evaluation of tumor-infiltrating mononuclear cells: detection of endogenous interferon- γ and tumor necrosis factor- in human colorectal adenocarcinomas. Cancer 1991 68 9 1937 1943 2-s2.0-0025933944
48. Zhang C. V., Cell Apoptosis 2007 New York, NY, USA Nova Science Publishers, Inc.
49. Mellier G., Huang S., Shenoy K., Pervaiz S., TRAILing death in cancer. Molecular Aspects of Medicine 2010 31 1 93 112 2-s2.0-77649190268 10.1016/j.mam.2009.12.002
50. Wiley S. R., Schooley K., Smolak P. J., Din W. S., Huang C.-P., Nicholl J. K., Sutherland G. R., Smith T. D., Rauch C., Smith C. A., Goodwin R. G., Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995 3 6 673 682 2-s2.0-13344285339 10.1016/1074-7613(95)90057-8
51. Falschlehner C., Schaefer U., Walczak H., Following TRAIL's path in the immune system. Immunology 2009 127 2 145 154 2-s2.0-65449152836 10.1111/j.1365-2567.2009.03058.x
52. Mitchell M. J., Wayne E., Rana K., Schaffer C. B., King M. R., TRAIL-coated leukocytes that kill cancer cells in the circulation. Proceedings of the National Academy of Sciences of the United States of America 2014 111 930 935
53. Vaculova A., Kaminskyy V., Jalalvand E., Surova O., Zhivotovsky B., Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL. Molecular Cancer 2010 9, article 87 2-s2.0-77951119197 10.1186/1476-4598-9-87
54. Secchiero P., Gonelli A., Carnevale E., Milani D., Pandolfi A., Zella D., Zauli G., TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 2003 107 17 2250 2256 2-s2.0-0038414629 10.1161/01.CIR.0000062702.60708.C4
55. Vaculová A., Hofmanová J., Souček K., Kozubík A., Different modulation of TRAIL-induced apoptosis by inhibition of pro-survival pathways in TRAIL-sensitive and TRAIL-resistant colon cancer cells. FEBS Letters 2006 580 28-29 6565 6569 2-s2.0-34547823047 10.1016/j.febslet. 2006.11.004
56. Vaculová A., Hofmanová J., Zatloukalová J., Kozubík A., Differences in TRAIL-induced changes of Mcl-1 expression among distinct human colon epithelial cell lines. Experimental Cell Research 2009 315 19 3259 3266 2-s2.0-70350408333 10.1016/j.yexcr.2009.09.019
57. Flusberg D. A., Roux J., Spencer S. L., Sorger P. K., Cells surviving fractional killing by TRAIL exhibit transient but sustainable resistance and inflammatory phenotypes. Molecular Biology of the Cell 2013 24 2186 2200
58. Falschlehner C., Emmerich C. H., Gerlach B., Walczak H., TRAIL signalling: decisions between life and death. International Journal of Biochemistry and Cell Biology 2007 39 7-8 1462 1475 2-s2.0-34447094000 10.1016/j.biocel.2007.02.007
59. Brost S., Koschny R., Sykora J., Stremmel W., Lasitschka F., Walczak H., Ganten T. M., Differential expression of the TRAIL/TRAIL-receptor system in patients with inflammatory bowel disease. Pathology Research and Practice 2010 206 1 43 50 2-s2.0-73649099092 10.1016/j.prp.2009.09.005
60. Koornstra J. J., Kleibeuker J. H., van Geelen C. M. M., Rijcken F. E. M., Hollema H., de Vries E. G. E., de Jong S., Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. Journal of Pathology 2003 200 3 327 335 2-s2.0-0037672290 10.1002/path.1364
61. Laguinge L. M., Samara R. N., Wang W., El-Deiry W. S., Corner G., Augenlicht L., Mishra L., Jessup J. M., DR5 receptor mediates anoikis in human colorectal carcinoma cell lines. Cancer Research 2008 68 3 909 917 2-s2.0-38849113981 10.1158/0008-5472.CAN-06-1806
62. Grosse-Wilde A., Voloshanenko O., Lawrence Bailey S., Longton G. M., Schaefer U., Csernok A. I., Schütz G., Greiner E. F., Kemp C. J., Walczak H., TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. The Journal of Clinical Investigation 2008 118 1 100 110 2-s2.0-38149122326 10.1172/JCI33061
63. Hoogwater F. J. H., Nijkamp M. W., Smakman N., Steller E. J. A., Emmink B. L., Westendorp B. F., Raats D. A. E., Sprick M. R., Schaefer U., van Houdt W. J., De Bruijn M. T., Schackmann R. C. J., Derksen P. W. B., Medema J.-P., Walczak H., Borel Rinkes I. H. M., Kranenburg O., Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells. Gastroenterology 2010 138 7 2357 2367 2-s2.0-77952829835 10.1053/j.gastro.2010.02.046
64. Hague A., Hicks D. J., Hasan F., Smartt H., Cohen G. M., Paraskeva C., MacFarlane M., Increased sensitivity to TRAIL-induced apoptosis occurs during the adenoma to carcinoma transition of colorectal carcinogenesis. British Journal of Cancer 2005 92 4 736 742 2-s2.0-14944367957 10.1038/sj.bjc.6602387
65. Hofmanová J., Vaculová A., Hyžd'alová M., Kozubík A., Response of normal and colon cancer epithelial cells to TNF-family apoptotic inducers. Oncology Reports 2008 19 567 573
66. Krammer P. H., Arnold R., Lavrik I. N., Life and death in peripheral T cells. Nature Reviews Immunology 2007 7 7 532 542 2-s2.0-34250874501 10.1038/nri2115
67. Abrams S. I., Positive and negative consequences of Fas/Fas ligand interactions in the antitumor response. Frontiers in Bioscience 2005 10 809 821 2-s2.0-26244451817
68. Lavrik I. N., Krammer P. H., Regulation of CD95/Fas signaling at the DISC. Cell Death and Differentiation 2012 19 1 36 41 2-s2.0-84856764253 10.1038/cdd.2011.155
69. Zimmerman M. A., Singh N., Martin P. M., Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells. American Journal of Physiology-Gastrointestinal and Liver Physiology 2012 302 12 G1405 G1415 10.1152/ajpgi.00543.2011
70. Broad Institute,. 2014, http://www.broadinstitute.org/tumorscape/pages/ portalHome.jsf
71. Ruiz-Ruiz C., Robledo G., Cano E., Redondo J. M., Lopez-Rivas A., Characterization of p53-mediated up-regulation of CD95 gene expression upon genotoxic treatment in human breast tumor cells. The Journal of Biological Chemistry 2003 278 34 31667 31675 2-s2.0-0041355344 10.1074/jbc.M304397200
72. Paschall A. V., Zimmerman M. A., Torres C. M., Ceramide targets xIAP and cIAP1 to sensitize metastatic colon and breast cancer cells to apoptosis induction to suppress tumor progression. BMC Cancer 2014 14, article 24 10.1186/1471-2407-14-24
73. Sayani F. A., Keenan C. M., van Sickle M. D., Amundson K. R., Parr E. J., Mathison R. D., Macnaughton W. K., Braun J. E. A., Sharkey K. A., The expression and role of Fas ligand in intestinal inflammation. Neurogastroenterology and Motility 2004 16 1 61 74 2-s2.0-1342288976 10.1046/j.1365-2982.2003.00457.x
74. Medema J. P., de Jong J., van Hall T., Melief C. J. M., Offringa R., Immune escape of tumors in vivo by expression of cellular FLICE- inhibitory protein. Journal of Experimental Medicine 1999 190 7 1033 1038 2-s2.0-0033523670 10.1084/jem.190.7.1033
75. Wittkopf N., Gunther C., Martini E., Cellular FLICE-like inhibitory protein secures intestinal epithelial cell survival and immune homeostasis by regulating caspase-8. Gastroenterology 2013 145 6 1369 1379 10.1053/j.gastro. 2013.08.059
76. Liu F., Bardhan K., Yang D., NF-kappaB directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor suppression. The Journal of Biological Chemistry 2012 287 25530 25540
77. Simopoulos A. P., Omega-3 fatty acids in health and disease and in growth and development. American Journal of Clinical Nutrition 1991 54 3 438 463 2-s2.0-0026094489
78. Matafome P., Santos-Silva D., Sena C. M., Seica R., Common mechanisms of dysfunctional adipose tissue and obesity-related cancers. Diabetes/Metabolism Research and Reviews 2013 29 4 285 295 10.1002/dmrr.2395
79. Day S. D., Enos R. T., McClellan J. L., Steiner J. L., Velazquez K. T., Murphy E. A., Linking inflammation to tumorigenesis in a mouse model of high-fat-diet-enhanced colon cancer. Cytokine 2013 64 454 462
80. Tammariello A. E., Milner J. A., Mouse models for unraveling the importance of diet in colon cancer prevention. Journal of Nutritional Biochemistry 2010 21 2 77 88 2-s2.0-74349102283 10.1016/j.jnutbio.2009.09.014
81. Zeng H., Lazarova D. L., Obesity-related colon cancer: dietary factors and their mechanisms of anticancer action. Clinical and Experimental Pharmacology and Physiology 2012 39 2 161 167 2-s2.0-84856426334 10.1111/j.1440-1681.2011.05518.x
82. Flachs P., Rossmeisl M., Bryhn M., Kopecky J., Cellular and molecular effects of n-3 polyunsaturated fatty acids on adipose tissue biology and metabolism. Clinical Science 2009 116 1 1 16 2-s2.0-60549108418 10.1042/CS20070456
83. Simopoulos A. P., Genetic variants in the metabolism of omega-6 and omega-3 fatty acids: their role in the determination of nutritional requirements and chronic disease risk. Experimental Biology and Medicine 2010 235 7 785 795 2-s2.0-77953742101 10.1258/ebm.2010.009298
84. Simopoulos A. P., The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomedicine and Pharmacotherapy 2002 56 8 365 379 2-s2.0-0036776120 10.1016/S0753-3322(02)00253-6
85. Kang J. X., Balance of omega-6/omega-3 essential fatty acids is important for health. The evidence from gene transfer studies. World Review of Nutrition and Dietetics 2005 95 93 102 2-s2.0-33644656493
86. Kremmyda L. S., Tvrzicka E., Stankova B., Zak A., Fatty acids as biocompounds: their role in human metabolism, health and disease: a review-part 2: fatty acid physiological roles and applications in human health and disease. Biomedical Papers of the Medical Faculty of the University Palacký Olomouc, Czechoslovakia 2011 155 3 195 218 2-s2.0-80054121197 10.5507/bp.2011.052
87. D'Archivio M., Scazzocchio B., Giammarioli S., omega3-PUFAs exert anti-inflammatory activity in visceral adipocytes from colorectal cancer patients. PLoS ONE 2013 8 e77432
88. Los D. A., Murata N., Membrane fluidity and its roles in the perception of environmental signals. Biochimica et Biophysica Acta 2004 1666 1-2 142 157 2-s2.0-7044224838 10.1016/j.bbamem.2004.08.002
89. Sinicrope F. A., Gill S., Role of cyclooxygenase-2 in colorectal cancer. Cancer and Metastasis Reviews 2004 23 1-2 63 75 2-s2.0-1242314857 10.1023/A:1025863029529
90. Medeiros A., Peres-Buzalaf C., Fortino Verdan F., Serezani C. H., Prostaglandin E2 and the suppression of phagocyte innate immune responses in different organs. Mediators of Inflammation 2012 2012 13 10.1155/2012/327568 327568
91. Barajas-Espinosa A., Ochoa-Cortes F., Moos M. P., Ramirez F. D., Vanner S. J., Funk C. D., Characterization of the cysteinyl leukotriene 2 receptor in novel expression sites of the gastrointestinal tract. American Journal of Pathology 2011 178 6 2682 2689 2-s2.0-79959473804 10.1016/j.ajpath.2011.02.041
92. Hawcroft G., Loadman P. M., Belluzzi A., Hull M. A., Effect of eicosapentaenoic acid on E-type prostaglandin synthesis and EP4 receptor signaling in human colorectal cancer cells. Neoplasia 2010 12 8 618 627 2-s2.0-77956040136 10.1593/neo.10388
93. Serhan C. N., Chiang N., Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. British Journal of Pharmacology 2008 153 supplement 1 S200 S215 2-s2.0-40349100270 10.1038/sj.bjp.0707489
94. Rudolph I. L., Kelley D. S., Klasing K. C., Erickson K. L., Regulation of cellular differentiation and apoptosis by fatty acids and their metabolites. Nutrition Research 2001 21 1-2 381 393 2-s2.0-0035107164 10.1016/S0271-5317(00) 00285-2
95. Diggle C. P., In vitro studies on the relationship between polyunsaturated fatty acids and cancer: tumour or tissue specific effects? Progress in Lipid Research 2002 41 3 240 253 2-s2.0-0036154858 10.1016/S0163-7827(01)00025-X
96. MacLean C. H., Newberry S. J., Mojica W. A., Khanna P., Issa A. M., Suttorp M. J., Lim Y.-W., Traina S. B., Hilton L., Garland R., Morton S. C., Effects of omega-3 fatty acids on cancer risk: a systematic review. Journal of the American Medical Association 2006 295 4 403 415 2-s2.0-31344478294 10.1001/jama.295.4.403
97. Moyad M. A., An introduction to dietary/supplemental omega-3 fatty acids for general health and prevention-part II. Urologic Oncology: Seminars and Original Investigations 2005 23 1 36 48 2-s2.0-18844372536 10.1016/j.urolonc. 2005.03.001
98. Hofmanová J., Souček K., Vaculová A., Kozubík A., Valacchi G., Davis P. A., Fatty acids in the modulation of reactive oxygen species balance in cancer. Oxidants in Biology: A Question of Balance 2008 chapter 6 Dordrecht, The Netherlands Springer 129 153 10.1007/978-1-4020-8399-0- 6
99. Abir F., Alva S., Kaminski D. L., Longo W. E., The role of arachidonic acid regulatory enzymes in colorectal disease. Diseases of the Colon and Rectum 2005 48 7 1471 1483 2-s2.0-21644443044 10.1007/s10350-005-0015-y
100. Lanas A., Sopeña F., Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complications. Gastroenterology Clinics of North America 2009 38 2 333 352 2-s2.0-65549161937 10.1016/j.gtc.2009.03.007
101. Teitelbaum J. E., Allan Walker W., Review: the role of omega 3 fatty acids in intestinal inflammation. Journal of Nutritional Biochemistry 2001 12 1 21 32 2-s2.0-0035147381 10.1016/S0955-2863(00)00141-8
102. Jho D. H., Cole S. M., Lee E. M., Espat N. J., Role of omega-3 fatty acid supplementation in inflammation and malignancy. Integrative Cancer Therapies 2004 3 2 98 111 2-s2.0-2442652852 10.1177/1534735404264736
103. Mills S. C., Windsor A. C., Knight S. C., The potential interactions between polyunsaturated fatty acids and colonic inflammatory processes. Clinical and Experimental Immunology 2005 142 2 216 228 2-s2.0-27644464295 10.1111/j.1365-2249.2005.02851.x
104. Reddy B. S., Burill C., Rigotty J., Effect of diets high in ω -3 and ω 6 fatty acids on initiation and postinitiation stages of colon carcinogenesis. Cancer Research 1991 51 2 487 491 2-s2.0-0026023962
105. Davidson L. A., Nguyen D. V., Hokanson R. M., Callaway E. S., Isett R. B., Turner N. D., Dougherty E. R., Wang N., Lupton J. R., Carroll R. J., Chapkin R. S., Chemopreventive n-3 polyunsaturated fatty acids reprogram genetic signatures during colon cancer initiation and progression in the rat. Cancer Research 2004 64 18 6797 6804 2-s2.0-4644359644 10.1158/0008-5472.CAN-04-1068
106. Calviello G., Serini S., Dietary Omega-3 Polyunsaturated Fatty Acids and Cancer 2010 New York, NY, USA Springer
107. Hudert C. A., Weylandt K. H., Lu Y., Wang J., Hong S., Dignass A., Serhan C. N., Kang J. X., Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proceedings of the National Academy of Sciences of the United States of America 2006 103 30 11276 11281 2-s2.0-33746625086 10.1073/pnas.0601280103
108. Pardini R. S., Nutritional intervention with omega-3 fatty acids enhances tumor response to anti-neoplastic agents. Chemico-Biological Interactions 2006 162 2 89 105 2-s2.0-33747060171 10.1016/j.cbi.2006.05.012
109. Surette M. E., The science behind dietary omega-3 fatty acids. Canadian Medical Association Journal 2008 178 2 177 180 2-s2.0-38349147105 10.1503/cmaj.071356
110. Calviello G., Serini S., Piccioni E., Pessina G., Antineoplastic effects of N-3 polyunsaturated fatty acids in combination with drugs and radiotherapy: preventive and therapeutic strategies. Nutrition and Cancer 2009 61 3 287 301 2-s2.0-67649396491 10.1080/01635580802582777
111. de Carlo F., Witte T. R., Hardman W. E., Claudio P. P., Omega-3 eicosapentaenoic acid decreases CD133 colon cancer stem-like cell marker expression while increasing sensitivity to chemotherapy. PLoS ONE 2013 8 e69760
112. Larsson S. C., Kumlin M., Ingelman-Sundberg M., Wolk A., Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. American Journal of Clinical Nutrition 2004 79 6 935 945 2-s2.0-3042767902
113. Chapkin R. S., Seo J., McMurray D. N., Lupton J. R., Mechanisms by which docosahexaenoic acid and related fatty acids reduce colon cancer risk and inflammatory disorders of the intestine. Chemistry and Physics of Lipids 2008 153 1 14 23 2-s2.0-43049172248 10.1016/j.chemphyslip.2008.02.011
114. Skender B., Vaculová A. H., Hofmanová J., Docosahexaenoic fatty acid (DHA) in the regulation of colon cell growth and cell death: a review. Biomedical Papers of the Medical Faculty of the University Palacký Olomouc, Czechoslovakia 2012 156 3 186 199 10.5507/bp.2012.093
115. Kaczmarczyk M. M., Miller M. J., Freund G. G., The health benefits of dietary fiber: beyond the usual suspects of type 2 diabetes mellitus, cardiovascular disease and color cancer. Metabolism: Clinical and Experimental 2012 61 1058 1066 2-s2.0-84857674228 10.1016/j.metabol.2012.01.017
116. Hamer H. M., Jonkers D., Venema K., Vanhoutvin S., Troost F. J., Brummer R.-J., Review article: the role of butyrate on colonic function. Alimentary Pharmacology and Therapeutics 2008 27 2 104 119 2-s2.0-37149022209 10.1111/j.1365-2036.2007.03562.x
117. Hofmanová J., Vaculová A., Kozubík A., Regulation of the metabolism of polyunsaturated fatty acids and butyrate in colon cancer cells. Current Pharmaceutical Biotechnology 2013 14 3 274 288
118. Tong X., Yin L., Giardina C., Butyrate suppresses Cox-2 activation in colon cancer cells through HDAC inhibition. Biochemical and Biophysical Research Communications 2004 317 2 463 471 2-s2.0-1842531133 10.1016/j.bbrc.2004.03.066
119. Ventham N. T., Kennedy N. A., Nimmo E. R., Satsangi J., Beyond gene discovery in inflammatory bowel disease: the emerging role of epigenetics. Gastroenterology 2013 145 293 308
120. Daroqui M. C., Augenlicht L. H., Transcriptional attenuation in colon carcinoma cells in response to butyrate. Cancer Prevention Research 2010 3 10 1292 1302 2-s2.0-77958573090 10.1158/1940-6207.CAPR-10-0083
121. Canani R. B., Costanzo M. D., Leone L., Pedata M., Meli R., Calignano A., Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World Journal of Gastroenterology 2011 17 12 1519 1528 2-s2.0-79955932718 10.3748/wjg.v17.i12.1519
122. Ganapathy V., Thangaraju M., Gopal E., Martin P. M., Itagaki S., Miyauchi S., Prasad P. D., Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS Journal 2008 10 1 193 199 2-s2.0-51249118120 10.1208/s12248-008-9022-y
123. Karaki S. I., Tazoe H., Hayashi H., Kashiwabara H., Tooyama K., Suzuki Y., Kuwahara A., Expression of the short-chain fatty acid receptor, GPR43, in the human colon. Journal of Molecular Histology 2008 39 2 135 142 2-s2.0-41049090425 10.1007/s10735-007-9145-y
124. Thibault R., Blachier F., Darcy-Vrillon B., de Coppet P., Bourreille A., Segain J.-P., Butyrate utilization by the colonic mucosa in inflammatory bowel diseases: a transport deficiency. Inflammatory Bowel Diseases 2010 16 4 684 695 2-s2.0-77949538579 10.1002/ibd.21108
125. Andriamihaja M., Chaumontet C., Tome D., Blachier F., Butyrate metabolism in human colon carcinoma cells: implications concerning its growth-inhibitory effect. Journal of Cellular Physiology 2009 218 1 58 65 2-s2.0-58149145317 10.1002/jcp.21556
126. Vondráček J., Sheard M. A., Krejčí P., Minksová K., Hofmanová J., Kozubík A., Modulation of death receptor-mediated apoptosis in differentiating human myeloid leukemia HL-60 cells. Journal of Leukocyte Biology 2001 69 794 802
127. Štika J., Vondráček J., Hofmanová J., Šimek V., Kozubík A., MK-886 enhances tumour necrosis factor-alpha-induced differentiation and apoptosis. Cancer Letters 2006 237 263 271
128. Procházková J., Stixová L., Souček K., Hofmanová J., Kozubík A., Monocytic differentiation of leukemic HL-60 cells induced by co-treatment with TNF- and MK886 requires activation of pro-apoptotic machinery. European Journal of Haematology 2009 83 1 35 47 2-s2.0-67649325460 10.1111/j.1600-0609.2009.01240.x
129. Kovaříková M., Hofmanová J., Souček K., Kozubík A., The effects of TNF- and inhibitors of arachidonic acid metabolism on human colon HT-29 cells depend on differentiation status. Differentiation 2004 72 1 23 31 2-s2.0-7444227449 10.1111/j.1432-0436.2004. 07201006.x
130. Hofmanová J., Vaculová A., Kozubík A., Polyunsaturated fatty acids sensitize human colon adenocarcinoma HT-29 cells to death receptor-mediated apoptosis. Cancer Letters 2005 218 1 33 41 2-s2.0-11444267603 10.1016/j.canlet.2004.07.038
131. Vaculová A., Hofmanová J., Anděra L., Kozubík A., TRAIL and docosahexaenoic acid cooperate to induce HT-29 colon cancer cell death. Cancer Letters 2005 229 43 48
132. Vondálová Blanářová O., Jelínková I., Szöor A., Skender B., Soucek K., Horváth V., Vaculová A., Andera L., Sova P., Szöllosi J., Hofmanová J., Vereb G., Kozubík A., Cisplatin and a potent platinum(IV) complex-mediated enhancement of TRAIL-induced cancer cells killing is associated with modulation of upstream events in the extrinsic apoptotic pathway. Carcinogenesis 2011 32 1 42 51 2-s2.0-79952117634
133. Hofmanová J., Vaculová A., Koubková Z., Hýžďalová M., Kozubík A., Human fetal colon cells and colon cancer cells respond differently to butyrate and PUFAs. Molecular Nutrition & Food Research 2009 53 supplement 1 S102 S113
134. Kočí L., Hýžd'alová M., Vaculová A., Hofmanová J., Kozubík A., Detachment-mediated resistance to TRAIL-induced apoptosis is associated with stimulation of the PI3K/Akt pathway in fetal and adenocarcinoma epithelial colon cells. Cytokine 2011 55 1 34 39 2-s2.0-79956355937 10.1016/j.cyto.2011.03.013
135. Accioly M. T., Pacheco P., Maya-Monteiro C. M., Carrossini N., Robbs B. K., Oliveira S. S., Kaufmann C., Morgado-Diaz J. A., Bozza P. T., Viola J. P. B., Lipid bodies are reservoirs of cyclooxygenase-2 and sites of prostaglandin-E2 synthesis in colon cancer cells. Cancer Research 2008 68 6 1732 1740 2-s2.0-40949096164 10.1158/0008-5472.CAN-07-1999
136. Ma D. W. L., Seo J., Davidson L. A., Callaway E. S., Fan Y.-Y., Lupton J. R., Chapkin R. S., n-3 PUFA alter caveolae lipid composition and resident protein localization in mouse colon. The FASEB Journal 2004 18 9 1040 1042 2-s2.0-6944240423 10.1096/fj.03-1430fje
137. Stillwell W., Shaikh S. R., Zerouga M., Siddiqui R., Wassal S. R., Docosahexaenoic acid affects cell signaling by altering lipid rafts. Reproduction Nutrition Development 2005 45 5 559 579 2-s2.0-27244437222 10.1051/rnd:2005046
138. Seo J., Barhoumi R., Johnson A. E., Lupton J. R., Chapkin R. S., Docosahexaenoic acid selectively inhibits plasma membrane targeting of lipidated proteins. The FASEB Journal 2006 20 6 770 772 2-s2.0-33646254135 10.1096/fj.05-4683fje
139. Rogers K. R., Kikawa K. D., Mouradian M., Hernandez K., McKinnon K. M., Ahwah S. M., Pardini R. S., Docosahexaenoic acid alters epidermal growth factor receptor-related signaling by disrupting its lipid raft association. Carcinogenesis 2010 31 9 1523 1530 2-s2.0-77956295532 10.1093/carcin/bgq111
140. Kagan V. E., Tyurina Y. Y., Bayir H., Chu C. T., Kapralov A. A., Vlasova I. I., Belikova N. A., Tyurin V. A., Amoscato A., Epperly M., Greenberger J., DeKosky S., Shvedova A. A., Jiang J., The "pro-apoptotic genies" get out of mitochondria: oxidative lipidomics and redox activity of cytochrome c/cardiolipin complexes. Chemico-Biological Interactions 2006 163 1-2 15 28 2-s2.0-33750049685 10.1016/j.cbi.2006.04.019
141. Rohrbach S., Effects of dietary polyunsaturated fatty acids on mitochondria. Current Pharmaceutical Design 2009 15 36 4103 4116 2-s2.0-71849113430 10.2174/138161209789909692
142. Hong M. Y., Chapkin R. S., Barhoumi R., Burghardt R. C., Turner N. D., Henderson C. E., Sanders L. M., Fan Y.-Y., Davidson L. A., Murphy M. E., Spinka C. M., Carroll R. J., Lupton J. R., Fish oil increases mitochondrial phospholipid unsaturation, upregulating reactive oxygen species and apoptosis in rat colonocytes. Carcinogenesis 2002 23 11 1919 1925 2-s2.0-0036848492
143. Mbodji K., Charpentier C., Guerin C., Adjunct therapy of n-3 fatty acids to 5-ASA ameliorates inflammatory score and decreases NF-kappaB in rats with TNBS-induced colitis. The Journal of Nutritional Biochemistry 2013 24 700 705
144. Gravaghi C., la Perle K. M. D., Ogrodwski P., Kang J. X., Quimby F., Lipkin M., Lamprecht S. A., Cox-2 expression, PGE2 and cytokines production are inhibited by endogenously synthesized n-3 PUFAs in inflamed colon of fat-1 mice. Journal of Nutritional Biochemistry 2011 22 4 360 365 2-s2.0-78751520397 10.1016/j.jnutbio.2010.03.003
145. Algamas-Dimantov A., Davidovsky D., Ben-Ari J., Amelioration of diabesity-induced colorectal ontogenesis by omega-3 fatty acids in mice. The Journal of Lipid Research 2012 53 1056 1070
146. Meydani S. N., Dietary modulation of cytokine production and biologic functions. Nutrition Reviews 1990 48 10 361 369 2-s2.0-0025059425
147. Ribardo D. A., Peterson J. W., Chopra A. K., Phospholipase A2-activating protein-an important regulatory molecule in modulating cyclooxygenase-2 and tumor necrosis factor production during inflammation. Indian Journal of Experimental Biology 2002 40 2 129 138 2-s2.0-0036007972
148. Sassa T., Suto S., Okayasu Y., Kihara A., A shift in sphingolipid composition from C24 to C16 increases susceptibility to apoptosis in HeLa cells. Biochimica et Biophysica Acta 2012 1821 7 1031 1037 10.1016/j.bbalip.2012.04. 008
149. Hayakawa M., Ishida N., Takeuchi K., Shibamoto S., Hori T., Oku N., Ito F., Tsujimoto M., Arachidonic acid-selective cytosolic phospholipase A2 is crucial in the cytotoxic action of tumor necrosis factor. The Journal of Biological Chemistry 1993 268 15 11290 11295 2-s2.0-0027161634
150. Cao Y., Pearman A. T., Zimmerman G. A., McIntyre T. M., Prescott S. M., Intracellular unesterified arachidonic acid signals apoptosis. Proceedings of the National Academy of Sciences of the United States of America 2000 97 21 11280 11285 2-s2.0-0034633638
151. Bannenberg G. L., Therapeutic applicability of anti-inflammatory and proresolving polyunsaturated fatty acid-derived lipid mediators. TheScientificWorldJOURNAL 2010 10 676 712 2-s2.0-77952897873 10.1100/tsw.2010.57
152. Kinsella J. E., Lipids, membrane receptors, and enzymes: effects of dietary fatty acids. Journal of Parenteral and Enteral Nutrition 1990 14 5 200S 217S 2-s2.0-0025080131
153. di Marzo V., Arachidonic acid and eicosanoids as targets and effectors in second messenger interactions. Prostaglandins Leukotrienes and Essential Fatty Acids 1995 53 4 239 254 2-s2.0-0028863120
154. Nowak J., Weylandt K. H., Habbel P., Wang J., Dignass A., Glickman J. N., Kang J. X., Colitis-associated colon tumorigenesis is suppressed in transgenic mice rich in endogenous n-3 fatty acids. Carcinogenesis 2007 28 9 1991 1995 2-s2.0-34848875143 10.1093/carcin/bgm166
155. Sampath H., Ntambi J. M., Polyunsaturated fatty acid regulation of genes of lipid metabolism. Annual Review of Nutrition 2005 25 317 340 2-s2.0-23944435868 10.1146/annurev.nutr.25.051804.101917
156. Edwards I. J., O'Flaherty J. T., Omega-3 fatty acids and PPAR γ in cancer. PPAR Research 2008 2008 14 2-s2.0-53149131328 10.1155/2008/358052 358052
157. Kliewer S. A., Sundseth S. S., Jones S. A., Brown P. J., Wisely G. B., Koble C. S., Devchand P., Wahli W., Willson T. M., Lenhard J. M., Lehmann J. M., Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors and γ Proceedings of the National Academy of Sciences of the United States of America 1997 94 9 4318 4323 2-s2.0-0006132932 10.1073/pnas.94.9.4318
158. Han J., Soletti R. C., Sadarangani A., Nuclear expression of beta-catenin promotes RB stability and resistance to TNF-induced apoptosis in colon cancer cells. Molecular Cancer Research 2013 11 207 218
159. Narayanan B. A., Narayanan N. K., Simi B., Reddy B. S., Modulation of inducible nitric oxide synthase and related proinflammatory genes by the omega-3 fatty acid docosahexaenoic acid in human colon cancer cells. Cancer Research 2003 63 5 972 979 2-s2.0-0037374461
160. Hernandez A., Thomas R., Smith F., Sandberg J., Kim S., Chung D. H., Evers B. M., Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis. Surgery 2001 130 2 265 272 2-s2.0-0034908231 10.1067/msy.2001.115897
161. Ruemmele F. M., Dionne S., Qureshi I., Sarma D. S. R., Levy E., Seidman E. G., Butyrate mediates Caco-2 cell apoptosis via up-regulation of pro-apoptotic BAK and inducing caspase-3 mediated cleavage of poly-(ADP-ribose) polymerase (PARP). Cell Death and Differentiation 1999 6 8 729 735 2-s2.0-0032869696
162. Jones S. A., Butler R. N., Sanderson I. R., Wilson J. W., The effect of specific caspase inhibitors on TNF- and butyrate-induced apoptosis of intestinal epithelial cells. Experimental Cell Research 2004 292 1 29 39 2-s2.0-0346725848 10.1016/j.yexcr.2003.08.005
163. Orzechowska S., Pajak B., Gajkowska B., Orzechowski A., Cholesterol level determines viability and mitogenicity, but it does not affect sodium butyrate-dependent sensitization of Colo 205 cells to TNF- -induced apoptosis. Oncology Reports 2011 25 2 573 582 2-s2.0-78651366838 10.3892/or.2010.1081
164. Tran S. E. F., Holmström T. H., Ahonen M., Kähäri V.-M., Eriksson J. E., MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. The Journal of Biological Chemistry 2001 276 19 16484 16490 2-s2.0-0035844129 10.1074/jbc.M010384200
165. Giardina C., Boulares H., Inan M. S., NSAIDs and butyrate sensitize a human colorectal cancer cell line to TNF- and Fas ligation: the role of reactive oxygen species. Biochimica et Biophysica Acta 1999 1448 3 425 438 2-s2.0-0032955276 10.1016/S0167-4889(98)00156-6
166. Kovaříková M., Pacherník J., Hofmanová J., Zadák Z., Kozubík A., TNF-alpha modulates the differentiation induced by butyrate in the HT-29 human colon adenocarcinoma cell line. European Journal of Cancer 2000 36 14 1844 1852
167. Gong J., Yang D., Kohanim S., Humphreys R., Broemeling L., Kurzrock R., Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies. Molecular Cancer Therapeutics 2006 5 12 2991 3000 2-s2.0-33846185483 10.1158/1535-7163.MCT-06-0188
168. Pajak B., Gajkowska B., Orzechowski A., Position of STAT-1 in cycloheximide-dependent apoptosis triggered by TNF- in human colorectal COLO 205 cancer cell line; role of polyphenolic compounds. Journal of Physiology and Pharmacology 2005 56 supplement 3 119 141 2-s2.0-31144450936
169. Lombard M. A., Wallace T. L., Kubicek M. F., Petzold G. L., Mitchell M. A., Hendges S. K., Wilks J. W., Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (TIMP)-2, but not TIMP-1, inhibit shedding of tumor necrosis factor- receptors in a human colon adenocarcinoma (Colo 205) cell line. Cancer Research 1998 58 17 4001 4007 2-s2.0-0032170034
170. Pajak B., Gajkowska B., Orzechowski A., Cycloheximide-mediated sensitization to TNF- -induced apoptosis in human colorectal cancer cell line COLO 205; role of FLIP and metabolic inhibitors. Journal of Physiology and Pharmacology 2005 56 supplement 3 101 118 2-s2.0-31144434529
171. Pajak B., Orzechowski A., IFN-alpha competes with TNF-alpha for STAT-1alpha; molecular basis for immune escape of human colon adenocarcinoma COLO 205 cells. Oncology Reports 2007 18 4 1039 1045 2-s2.0-38449105965
172. Cesaro P., Raiteri E., Démoz M., Castino R., Baccino F. M., Bonelli G., Isidoro C., Expression of protein kinase C β 1 confers resistance to TNF -and paclitaxel-induced apoptosis in HT-29 colon carcinoma cells. International Journal of Cancer 2001 93 2 179 184 2-s2.0-0035879754 10.1002/ijc.1314
173. Velázquez O. C., Seto R. W., Rombeau J. L., The scientific rationale and clinical application of short-chain fatty acids and medium-chain triacylglycerols. Proceedings of the Nutrition Society 1996 55 1 49 78 2-s2.0-0030093633
174. Inan M. S., Rasoulpour R. J., Yin L., Hubbard A. K., Rosenberg D. W., Giardina C., The luminal short-chain fatty acid butyrate modulates NF- B activity in a human colonic epithelial cell line. Gastroenterology 2000 118 4 724 734 2-s2.0-0034062353
175. Yin L., Laevsky G., Giardina C., Butyrate suppression of colonocyte NF- B activation and cellular proteasome activity. The Journal of Biological Chemistry 2001 276 48 44641 44646 2-s2.0-0035977063 10.1074/jbc.M105170200
176. Hýžd'alová M., Hofmanová J., Pacherník J., Vaculová A., Kozubík A., The interaction of butyrate with TNF-alpha during differentiation and apoptosis of colon epithelial cells: role of NF-kappaB activation. Cytokine 2008 44 33 43
177. Butzner J. D., Parmar R., Bell C. J., Dalal V., Butyrate enema therapy stimulates mucosal repair in experimental colitis in the rat. Gut 1996 38 4 568 573 2-s2.0-0029930039
178. Segain J. P., Raingeard de la Blétière D., Bourreille A., Leray V., Gervois N., Rosales C., Ferrier L., Bonnet C., Blottière H. M., Butyrate inhibits inflammatory responses through NF B inhibition: implications for Crohn's disease. Gut 2000 47 3 397 403 2-s2.0-0033863238 10.1136/gut.47.3.397
179. Kim Y. H., Park J. W., Lee J. Y., Kwon T. K., Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis 2004 25 10 1813 1820 2-s2.0-6444242600 10.1093/carcin/bgh188
180. Hamed H. A., Yamaguchi Y., Fisher P. B., Grant S., Dent P., Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells. Journal of Cellular Physiology 2013 228 10 1996 2005 10.1002/jcp.24362
181. Earel J. K. Jr., VanOosten R. L., Griffith T. S., Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Cancer Research 2006 66 1 499 507 2-s2.0-31544432335 10.1158/0008-5472.CAN-05-3017
182. Bangert A., Cristofanon S., Eckhardt I., Abhari B. A., Kolodziej S., Häcker S., Vellanki S. H. K., Lausen J., Debatin K.-M., Fulda S., Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP. Oncogene 2012 31 4677 4688 2-s2.0-84856020876 10.1038/onc.2011.614
183. Giardina C., Inan M. S., Nonsteroidal anti-inflammatory drugs, short-chain fatty acids, and reactive oxygen metabolism in human colorectal cancer cells. Biochimica et Biophysica Acta 1998 1401 3 277 288 2-s2.0-0032485472 10.1016/S0167-4889(97)00140-7
184. Dupertuis Y. M., Meguid M. M., Pichard C., Advancing from immunonutrition to a pharmaconutrition: a gigantic challenge. Current Opinion in Clinical Nutrition and Metabolic Care 2009 12 4 398 403 2-s2.0-68049091023 10.1097/MCO.0b013e32832c4ce1
185. Lands B., A critique of paradoxes in current advice on dietary lipids. Progress in Lipid Research 2008 47 2 77 106 2-s2.0-39749183516 10.1016/j.plipres.2007.12.001
186. Hagi A., Nakayama M., Shinzaki W., Haji S., Ohyanagi H., Effects of the ω -6: ω -3 fatty acid ratio of fat emulsions on the fatty acid composition in cell membranes and the anti-inflammatory action. Journal of Parenteral and Enteral Nutrition 2010 34 3 263 270 2-s2.0-77953669024 10.1177/0148607109357625
187. Han Y. Y., Lai S. L., Ko W. J., Chou C. H., Lai H. S., Effects of fish oil on inflammatory modulation in surgical intensive care unit patients. Nutrition in Clinical Practice 2012 27 1 91 98 2-s2.0-84856720829 10.1177/0884533611429796
188. Wanten G. J. A., Calder P. C., Immune modulation by parenteral lipid emulsions. American Journal of Clinical Nutrition 2007 85 5 1171 1184 2-s2.0-34248344638
189. Berquin I. M., Edwards I. J., Chen Y. Q., Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer Letters 2008 269 2 363 377 2-s2.0-51349137876 10.1016/j.canlet.2008.03.044
190. Calder P. C., Symposium 4: hot topics in parenteral nutrition. Rationale for using new lipid emulsions in parenteral nutrition and a review of the trials performed in adults. Proceedings of the Nutrition Society 2009 68 3 252 260 2-s2.0-70349261950 10.1017/S0029665109001268
191. Waitzberg D. L., Torrinhas R. S., Fish oil lipid emulsions and immune response: what clinicians need to know. Nutrition in Clinical Practice 2009 24 4 487 499 2-s2.0-70349568379 10.1177/0884533609339071
192. van Beelen V. A., Spenkelink B., Mooibroek H., Sijtsma L., Bosch D., Rietjens I. M. C. M., Alink G. M., An n-3 PUFA-rich microalgal oil diet protects to a similar extent as a fish oil-rich diet against AOM-induced colonic aberrant crypt foci in F344 rats. Food and Chemical Toxicology 2009 47 2 316 320 2-s2.0-58149503743 10.1016/j.fct.2008.11.014
193. Russell F. D., Burgin-Maunder C. S., Distinguishing health benefits of eicosapentaenoic and docosahexaenoic acids. Marine Drugs 2012 10 2535 2559
194. Garib R., Garla P., Torrinhas R. S., Bertevello P. L., Logullo A. F., Waitzberg D. L., Effects of parenteral fish oil lipid emulsions on colon morphology and cytokine expression after experimental colitis. Nutrición Hospitalaria 2013 28 3 849 856 10.3305/nh.2013.28.3.6404
195. Tisdale M. J., The 'cancer cachectic factor'. Supportive Care in Cancer 2003 11 2 73 78 2-s2.0-0037561931
196. Pajak B., Orzechowska S., Pijet B., Pijet M., Pogorzelska A., Gajkowska B., Orzechowski A., Crossroads of cytokine signaling-the chase to stop muscle cachexia. Journal of Physiology and Pharmacology 2008 59 supplement 9 251 264 2-s2.0-64049106742
197. Deans C., Wigmore S. J., Systemic inflammation, cachexia and prognosis in patients with cancer. Current Opinion in Clinical Nutrition and Metabolic Care 2005 8 3 265 269 2-s2.0-17844368604
198. Balkwill F., TNF- in promotion and progression of cancer. Cancer and Metastasis Reviews 2006 25 3 409 416 2-s2.0-33845524008 10.1007/s10555-006-9005- 3
199. Raqib R., Sarker P., Mily A., Efficacy of sodium butyrate adjunct therapy in shigellosis: a randomized, double-blind, placebo-controlled clinical trial. BMC Infectious Diseases 2012 12, article 111